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1. Introduction 
Peptic ulcer (PU) was a local gastrointestinal lesion due to gastric fluid, gastric acid and 
pepsin insult. The lesion may involve in mucosal layer, submucosal or even muscle and 
plasma layer in duodenum and stomach. It was characterized as not only easy to relapse but 
also hard to prevent (Wang et al., 1998). Its etiology and mechanism was very sophisticated 
due to the imbalance between offensive factors (gastric acid, pepsin, H. pylori and NSAIDs) 
and defensive factors (gastric mucus, bicarbonates and blood flow of gastric mucosa) ( 
Hoogerwerf & Pasricha, 2006). There were at least 3 defensive barriers in the gastric wall to 
resist gastric acid and pepsin: the mucus-bicarbonates barrier that includes mucus and the 
bicarbonates grade in the mucus, the mucosa barrier that is the tight conjunction structure 
among gastric epithelial cells, and the blood flow in mucosa that provides oxygen and 
nutrition to mucosa and support the turnover of gastric epithelium and mucus. H. pylori and 
NSAIDs were gastric mucosa’s offensive factors (Tytgat, 2000). Although they cause peptic 
ulcer by destroying the gastric barrier function, the mechanism was not clear. There were 
arguments for their simultaneous effects on peptic ulcer (Fendrick et al., 2001). Therefore, it 
is important to clarify the relationship between H. pylori and NSAIDs, especially when both 
cause simultaneously the damage to gastric mucosa. 
2. H. pylori and peptic ulcer 
H. pylori results in peptic ulcer through damaging gastric mucus and mucosa barriers, and 
enhancing gastric acid secretion. 
2.1 Damages of gastric mucus and mucosa barriers 
When H. pylori infects the stomach, it can produce cytotoxin-associated gene A protein 
(CagA), vacuolating cytotoxin A (VacA), urease, mucus enzyme, lipase and phospholipase 
to injure the gastric mucus and mucosa barriers, and finally results in the peptic ulcer with 
the combination of gastric acid and pepsin. 
Vacuolating cytotoxin and cytotoxin-associated protein: VacA is expressed in H. pylori and 
results in vacuolar degeneration in gastric epithelium through interfering ion transport 
protein, eg. vacuolar ATPase (Leunk et al., 1988). CagA is up-regulated in VacA+ strain and 
related to VacA activity. 60~70% of H. pylori strains express CagA and thereby induce host 
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cells to produce cytokines, enhance inflammatory reaction and damage the gastric mucosa 
(Ghira et al., 1995). CagA is immunogenic and induces gastric epithelial cell to produce 
interleukine-8 (IL-8) that causes strong immunoreactions and results in gastric mucosa 
injury (Ernst et al., 1994). 
Urease: H. pylori can produce urease. This enzyme locates on the H. pylori’s surface and 
introcytoplasma (Phadnis et al., 1996; Bode et al., 1989) and hydrolyses urea into ammonia. 
Ammonia can decrease the content of mucin in mucus and destroy the integrity of the ion 
in mucus, and finally decline the function of mucus barrier that results in the diffusion of 
hydrogen ion back to the stomach wall and the erosion of mucosa layer (Hazell et al., 
1986). Ammonia can also deprive alpha-ketoglutaric acid that is a middle metabolic 
substance in Kreb’s cycle, and thus, this cycle is blocked and the metabolism of cells is 
interfered, and finally the ATP production decreases and the Na+-K+ pump on the cellular 
membrane is out of order. It may result in cellular edema, degeneration and necrosis, and 
the barriers of mucus and mucosa are finally destroyed and the ulcer is formed (Marshall, 
1994). The hydroxy created from ammonia and water has cytotoxic effect on gastric 
mucosa. A high concentration of ammonia can cause cellular vacuolar degeneration (Xu et 
al., 1990). Urease can also cause directly the tissue damage of host (Windsor et al., 2000). 
H. pylori can stimulate neutrophils and cause oxidative burst, and thereby result in the 
production of H2O2 and oxygenate oxy-chloride ion. This ion can further combine 
ammonia and form more toxic monochloramine that participates in the process of mucosa 
injury (Sarosiek et al., 1989). The urea may serve as leukocyte chemotactic factor to attract 
inflammatory cells, cause local inflammation in the stomach, and damage indirectly the 
gastric epithelium.  
Mucus enzyme and pepsin: H. pylori can produce mucolytic enzyme that causes the gastric 
mucous degradation. The degraded mucus losses its viscosity and elasticity and thus, allows 
the diffusion of hydrogen ion back to the stomach wall and the erosion of mucosa layer. The 
decreased viscosity of mucus benefits the movement of H. pylori and makes H. pylori easier 
to plant on the stomach wall. The decomposed mucus can also provide nutrition necessary 
to H. pylori (Beales et al., 1996). H. pylori can also generate an extracellular protease that was 
able to split the polymer of glycoprotein in gastric mucus and wipe out the gastric mucous 
barrier so as to allow the gastric epithelium to contact directly with attack factors such as 
gastric acid, pepsin, cholic acid and drugs. Finally, the gastric epithelial erosion appears 
(Kawano et al., 1990). 
Lipase and phospholipase: the normal cell membrane is composed of double phospholipid 
layers. H. pylori can produce phospholipase A that hydrolyzes palmityl lecithin into free 
palmitic acid and lysolecithin and thereby destroy the integrity of the cellular membrane 
(Goggin et al., 1991). The lipid and phospholipid in the gastric mucus play an important role 
in the maintenance of mucous viscosity and hydrophobic characters and in the prevention 
of hydrogen ion from diffusion back to the stomach wall (Goggin et al., 1991). The lipase and 
phospholipase A can hydrolyze lipid and phospholipid in the mucus and thus obliterate the 
function of mucous barrier. Phospholipase A can also enhance the release of arachidonic 
acid and generate inflammatory media such as prostaglandin and thromboxane that induce 
inflammatory reaction. The metabolism of phospholipid, such as lysolecithin, also has 
cytotoxic effect (Lewis et al., 1990). 
Alcoholic dehydrogenase: Alcoholic dehydrogenase generated by H. pylori can oxygenate 
alcohol into acetaldehyde that is a strong oxidizer and causes the injury of mucosa. 
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Lipopolysaccharide (LPS): LPS produced by H. pylori can stimulate gastric epithelial cell to 
secrets IL-8 that can induce local inflammatory reaction in infected stomach. LPS also 
stimulates the pepsinogen secretion in gastric epithelium. Pepsin hydrolyses the protein in 
gastric epithelium, originates epithelial injury and causes ulceration (Young et al., 1992). LPS 
from H. pylori has similar antigenic determinants to human being, such as Lewis type 2, e.g. 
Lewis X and Lewis Y. These similar antigenic determinants also distribute in the surface of 
parietal cell and gastric gland. The patient with H. pylori infection may generate antibody for 
Lewis antigenic determinants. Therefore, the mucosa barrier will be injured by autoimmune 
reaction (Appelmelk et al., 1996). 
Free radical: When H. pylori infects the stomach, it can adhere to gastric epithelium via its 
surface structure such as N-acetylneuraminic lactose fibril haemogglutinin, extra cellular S 
adhesin and Lewis B blood-group antigen adhesin, etc (Lundstrom et al., 2001; Domingo et 
al., 1999; Dundon et al., 2001; McGee et al., 1999) . Neutrophil chemotactic factors such as 
VacA, CagA and neutrophil activating protein (NAP) are released (Atherton et al., 1997; 
Naito et al., 2002; Satin et al., 2000; Yoshikawa et al., 2000). Furthermore, H. pylori stimulates 
gastric epithelium to secret interleukin-8 (Shiotani et al., 2002; Bhattacharyya et al., 2002) that 
is a strong neutrophil chemotactic factor. These white blood chemotactic factors result in the 
occurrence of inflammation. Neutrophils, monocytes, lymphocytes and macrophage may 
infiltrate into mucosa and release a big amount of free radicals. Lipids and proteins in 
epithelium are peroxidized, and the cellular structure and function were damaged, and 
finally the epithelial barrier was destroyed.  
Hemolysin: H. pylori can secret hemolysin that has cytotoxic effects, induces inflammatory 
reaction, and results in the injury of epithelial barrier (Wetherall et al., 1989). 
In addition, H.pylori inhibits the expression of constitutive nitric oxide (cNOS) and enhances 
the expression of inducible NOS (iNOS) that may lead to the overproduction of NO and the 
excessive generation of toxic radical peroxynitrate the is involved in the gastric cell 
inflammatory response and cellular damage (Brzozowski et al., 2006). 
2.2 Increases of gastric acid 
H. pylori causes the release of urease and the formation of ammonia. Ammonia increases the 
pH on the surface of epithelial. Consequently, the gastrin secretion increases. Gastrinemia 
stimulates parietal cell to secret gastric acid. Persistent gastrinemia causes the proliferation 
of parietal cell and the further production of gastric acid. Gastric acid is a strong attack 
factor and causes ulceration formation (Levi et al., 1989). Other study demonstrated that H. 
pylori inhibit the secretion of somatostatin (SS) in sinus ventriculi D cells. SS inhibits the 
secretion of gastrin in sinus ventriculi G cells. The reduction of somatostatin weakens the 
control of gastrin secretion and thus prolongs the postprandial gastric acid secretion and 
causes ulceration (Kaneko et al., 1992) . H. pylori has a growth inhibitory factor that inhibits 
the turnover of mucous epithelial cells.  
3. NSAIDs and ulceration 
NSAIDs, such as aspirin and indometacin, are effective drugs for anti-inflammation, anti-
rheumatics, antipyretics and analgesics. Furthermore, NSAIDs, due to their effect on anti 
platelet aggregation, are regular prophylaxis drugs for cardiac and brain vascular diseases 
(Tarnawski et al., 2003). NSAIDs can also decrease the rate of colonial and rectal cancer 
(Husain et al., 2002) and Alzheimer disease (Tarnawski et al., 2003b). Therefore, NSAIDs 
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are widely used. NSAIDs, however, have a serious side-effect causing gastric mucosa 
damage. 
3.1 NSAIDs direct mucosa damage 
Most of NSAIDs are weak organic acids as non-ion status under acidic environment in the 
stomach. NSAIDs can freely pass cellular membrane to intracellular where the environment 
is neutral. Intracellular NSAIDs can be dissociated into water soluble ion status. The 
intracellular concentration of NSAIDs is much higher than the extracellular one. Therefore, 
NSAIDs have a direct cytotoxic effect on gastric mucosa cells (Scheiman, 1996). 
Furthermore, NSAIDs inhibit mitochondrial oxidative phosphorylation so as to interfere 
energy metabolism, inhibit the expression of heat shock proteins (HSP) related to cellular 
membrane integrity (Wallace, 1997), originate the injury of epithelium and the cellular 
exfoliation, induce the release of various inflammatory factors, such as leukotriene B4 and 
histamine, and finally damage capillary vascular, increase vascular permeability and reduce 
blood flow into the mucosa (Wallace et al., 1990; Wallace et al., 1995). Another effect is that 
NSAIDs trigger gastric epithelium to release tumor necrosis factor alpha (TNF-α). TNF-α 
increases adhesive molecules and activates neutrophils (Wallace et al., 1995), which result in 
the gastric mucosa neutrophil infiltration, the submucosa capillary vascular constriction, the 
mucosa ischemia and hypoxia, the abnormal metabolism in epithelial cells, and finally the 
functional damage of mucus and mucosa barrier. 
3.2 NSAIDs inhibit the syntheses of prostaglandin 
Arachidonic acid may be produced from phospholipids in the membrane under catalysis of 
phospholipase A2. Arachidonic acid generates leukotrienes through lipoxidase and 
generates PGI2 and PGE2 through cyclo-oxygenase. Leukotrienes are involved in allergic 
reaction, leukocyte chemotaxis and inflammation. PGI2 has the effects on vasodilatation and 
platelet aggregation. PGE2 is capable of inducing inflammation, fever, pain, vasodilatation 
and gastric mucosa protection (Scheiman, 1996).  
NSAIDs may inhibit COX activity, interfere the metabolism of arachidonic acid, and 
decrease PG syntheses (Figure 1). Therefore, NSAIDs have the effects of anti-inflammation, 
antipyretics and analgesics. COX has two isoforms, one is constitutive or COX-1 and another 
is inducible or COX-2. COX-1 constantly expresses in gastrointestinal tract and platelets, 
controls the syntheses of PGI2, PGE2 and TXA2, regulates angiotasis, protests the mucosa of 
digestive tract from assault factors, and maintains the mucosa’s integrity. There is little or 
almost no COX-2 in the mucosa of stomach and intestine and the platelets in healthy people. 
LPS, interleukin-1 (IL-1) and many other inflammatory factors, however, can induce its 
production. COX-2 can increase dramatically in local inflammatory lesion. It may result in 
the increase of PGI2 and PGE2 that also participate in inflammatory reaction. The classic 
NSAIDs had no selective inhibition effect on COX-1 and COX-2. The inhibition of COX-2 
results in anti-inflammation, while inhibition of COX-1 causes side effects, i.e. to decrease 
PGI2 and PGE2 that have mucosa protective effects, decline the blood flow in gastric mucosa, 
decrease the provision of oxygen and nutrition, slow the turnover of mucosa cells, lessen the 
syntheses and secretion of mucus, damage the mucus and mucosa barriers, prolong the 
mucosa reparation, and finally cause mucosa erosion, ulceration and hemorrhage (Pawlik et 
al., 2002). Besides above effects, aspirin prolongs the recovery of ulceration. Its mechanism 
underlies on the inhibition of PG syntheses (Wang et al., 1989), the reduction of cellular 
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proliferation (Penney et al., 1994) and the decrease of blood flow at the ulcer margin (Hirose 
et al., 1991). 
4. The simultaneous effects of H. pyori and NSAIDs on gastric mucosa 
From above discussion, we know that H. pylori and NSAIDs are two important factors 
assaulting gastric mucosa and have the pivotal role in the peptic ulcer. Each has a different 
way to injure the gastric mucosa. It has been confirmed that H. pylori and NSAIDs are two 
independent offending factors (Grymer et al., 1984). However, the exact relationship remains 
to be clarified (Laine, 2002). H. pylori and NSAIDs may be irrelevant, additive or synergistic, 
or possibly antagonistic (Ji et al., 2003). 
4.1 H. pylori and NSAIDs are irrelevant 
Some studies demonstrated that NSAIDs should not impact H. pylori’s plantation (Maxton et 
al., 1990). The infection of H. pylori dose not increase the ulcerative risk in long term NSAIDs 
user (Kim et al., 1994). The epidemic investigation showed that NSAIDs did not affect the 
patient’s susceptibility to H. pylori (Graham et al., 1991; Barkin, 1998; Wilcox, 1997). NSAIDs 
dose not enhance the gastrointestinal toxicity to H. pylori carrier (Rybar et al., 2001). Clinical 
data demonstrated that H. pylori infection did not impinge on the degree and type of gastric 
mucosa injury by NSAIDs (Barkin, 1998; LANZA et al., 1991).  
 
 
Fig. 1. NSAIDs inhibit COX activity 
4.2 There is additive or synergistic relationship between H. pylori and NSAIDs 
H. pylori and NSAIDs are strong offensive factors (Chan et al., 1998). Both of them can 
destroy gastric barrier function. Eradication of H. pylori before using NSAIDs reduces the 
ulcerative rate (Bazzoli et al., 2001). The ulceration is easier to relapse in NSAIDs takers with 
H. pylori than those without H. pylori infection (Chan et al., 1998b). Furthermore, both H. 
pylori and NSAIDs increase permeability in the gastric epithelial cellular junction, and thus 
allow the gastric acid, pepsin and other endogenous offending factors to injure the gastric 
mucosa (Barr et al., 2000). H. pylori and NSAIDs act synergistically through pathways of 
inflammation in the development of ulcers and in ulcer bleeding (Figure 2). 
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4.3 Antagonistic action between H. pylori and NSAIDs 
NSAIDs have bacteriostatic and bactericidal activity against H. pylori (Shirin et al., 2006). 
NSAIDs inhibit COX-1 and COX-2. This inhibition declines PG synthesis, while H. pylori 
infection stimulates gastric mucosa to express COX-2 (Takahashi et al., 2000) so as to 
enhance PG syntheses. H. pylori accelerates healing of gastric ulcer induced by NSAIDs in 
rats due to that H. pylori stimulates the overexpression of COX-2 and the increase of PG 
synthesis, and consequently increases the production of vascular endothelial growth factor 
(VEGF) and the vascular proliferation. Meanwhile, PG also increases transforming growth 
factor alpha that causes the increase of cellular proliferation and the decrease of gastric acid 
(Konturek et al., 2002), and finally enhances the recovery of injured gastric mucosa. The 
clinical trial also demonstrated that the H. pylori infection rate was lower in NSAIDs user 
than those people without NSAIDs administration (Bianchi et al., 1996). It also verifies that 
there is antagonistic action between H. pylori and NSAIDs. 
In conclusion, H. pylori and NSAIDs are individual strong factors causing peptic ulcer, and 
their final mechanism is to wipe out barrier function. However, the investigations are 
conflicts when H. pylori and NSAIDs coexist. The reasons leading to this conflict may be the 
patient’s age, the different type of NSAIDs, the administration length of NSAIDs and the 
different strain of H. pylori and so on. 
 
 
Fig. 2. Helicobacter pylori and nonsteroidal anti-inflammatory drugs have synergistic effects 
on gastric mucosal damage. Both H. pylori infection and NSAID use have been found to 
independently and significantly increase the risk of gastric and duodenal mucosal damage 
and ulceration. H. pylori and NSAIDs act synergistically through pathways of inflammation 
in the development of ulcers and in ulcer bleeding (Yuan et al., 2006). 
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